Through cutting-edge science and medicine, Biogen discovers, develops and delivers innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases. Founded in 1978, Biogen is a pioneer in biotechnology and today the Company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis. Biogen also manufactures and commercializes biosimilars of advanced biologics. With approximately 7000 people worldwide, we are truly a global organization, headquartered in Cambridge, Massachusetts, which is also home to our research operations. Our international headquarters are based in Zug, Switzerland and we have world-class manufacturing facilities in North Carolina and Denmark. We offer therapies globally through direct affiliate presence in 30 countries and a network of distribution partners in over 50 additional countries. For more information, please visit www.biogen.com. Follow us on social media – Twitter, LinkedIn, Facebook, YouTube.

Cabot Corporation (NYSE: CBT) is a leading global specialty chemical and performance materials company headquartered in Boston, Massachusetts. We deliver performance solutions that solve customers'​ challenges today and prepare them to meet tomorrow's needs.

Sumitomo Pharma America (SMPA) is a science-based, technology-driven biopharmaceutical company focused on delivering therapeutic and scientific breakthroughs in areas of critical patient need in psychiatry and neurology, oncology, urology, women’s health, rare disease, and cell and gene therapies. SMPA was formed through the consolidation of Sumitomo Pharma’s U.S. affiliate companies including Sunovion Pharmaceuticals, Inc., Sumitomo Pharma America Holdings, Inc., Sumitomo Pharma Oncology, Inc., Sumitovant Biopharma, Inc., Myovant Sciences, Inc., Urovant Sciences, Inc. and Enzyvant Therapeutics, Inc. SMPA is a Sumitomo Pharma company. Community Guidelines: https://www.us.sumitomo-pharma.com/social-media/index.html

As a premier global high-performance silicones and specialties company, Momentive creates solutions that improve quality of life for people and enable a more sustainable future. Our products are the result of a tireless pursuit of progress where the sun never sets on our global marketing and R&D efforts, resulting in innovations that help propel our customers’ businesses forward and positively impact all aspects of life – today, tomorrow, and into the future.

Curia is a Contract Development and Manufacturing Organization with over 30 years of experience, an integrated network of 29 global sites and over 3,500 employees partnering with customers to make treatments broadly accessible to patients. Our biologics and small molecule offering spans discovery through commercialization, with integrated regulatory and analytical capabilities. Our scientific and process experts and state-of-the-art facilities deliver best-in-class experience across drug substance and drug product manufacturing. From curiosity to cure, we deliver every step to accelerate and sustain life-changing therapeutics. To learn more visit us at curiaglobal.com ************************************************** ⚠️NOTICE: Please Be Aware of False Employment Opportunities ************************************************** Please be aware there has been reported fraudulent activity within our industry regarding false offers being made to applicants and requests for personal information from individuals or organizations posing as company representatives. Any applicant who applies to Curia must submit their application through Curia’s career page at https://careers.curiaglobal.com. Applicants will only receive communication, including offer letters, from a curiaglobal.com email address. Please be aware that recent scams used email addresses that are similar to Curia addresses or use other public domain addresses such as gmail.com, yahoo.com and aol.com. Please confirm the sender’s email address prior to sharing your information.

Sarepta Therapeutics, headquartered in Cambridge, Massachusetts, is a global biotechnology company on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 programs in various stages of development. Our vast pipeline is driven by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing. For information on our Community Guidelines, please visit sarepta.com/community-guidelines. We want to share a reminder with all job seekers and candidates regarding the persistence of recruiting fraud. Please read a message about recruiting fraud and steps you can take to protect yourself here: https://www.sarepta.com/recruiting-fraud